The science is clear.Most Jamaicans aren't acting on it.
Jamaica has some of the highest rates of preventable chronic disease in the Caribbean. The conditions driving those numbers are detectable years before symptoms appear. That gap between detectable and detected is where LifeVitals operates.
What the data saysabout where we are.
Jamaica faces a chronic disease burden that is disproportionate even by Caribbean standards. Hypertension affects roughly one in three Jamaican adults. Type 2 diabetes rates are nearly three times the global average. Cardiovascular disease is the leading cause of premature death among working-age men.
These are not new statistics. The Jamaican healthcare system has known about this burden for decades. What has been harder to address is thedetection gap— the period, often measured in years, during which a condition is developing but no one knows about it because no one has looked.
The research is consistent across jurisdictions:the earlier a chronic condition is detected, the more manageable it is.Pre-diabetes caught at the HbA1c stage can be reversed with lifestyle intervention. Hypertension caught before it causes arterial damage is treated with medication, not with emergency care. The window between "early detection possible" and "symptoms appear" is exactly where proactive screening operates.
LifeVitals was built specifically for the Jamaican context — the conditions most prevalent here, the biomarkers most predictive for this population, and the reality that most Jamaicans have not had a comprehensive blood panel in the last two years, if ever.
Jamaican adults hashigh blood pressure— most without knowing it.
PAHO / Caribbean Health Research Council
Jamaica's Type 2 diabetes rate isthree times the global average.
WHO / Jamaica Ministry of Health data
Of global deaths are caused by chronic diseases —the majority preventablewith early detection.
WHO Global Health Observatory, 2023
Pre-diabetes can be detectableup to 10 years beforeType 2 diabetes onset via HbA1c testing.
New England Journal of Medicine, 2023
Four findings that makethe case for proactive screening.
These are the studies we return to when we explain why LifeVitals exists. Summarised plainly — with the source if you want to read further.
Early detection changesoutcomes — measurably.
Routine biomarker testing can detect diabetes, cardiovascular disease, liver and kidney dysfunction, and cancer riskyears before symptoms appear.Early detection allows for lifestyle interventions and timely treatment that significantly reduce mortality — the evidence base here is robust and consistent across multiple populations.
New England Journal of Medicine · 2023
80% of prediabetics and hypertensive patientsshow no symptoms.
JAMA's 2022 review confirmed what clinicians have known for years: the most dangerous phase of chronic disease development is the asymptomatic phase.Feeling fine is not clinical evidence of anything.Routine lab testing is the only way to identify silent warning signs before irreversible damage occurs — there is no clinical alternative.
Journal of the American Medical Association · 2022
Preventive screening reduces long-termhealthcare costs by 40%.
The Lancet's analysis found that preventive screenings cut long-term healthcare expenses through reduced emergency care and hospitalisations.The economics of early detection compound in the patient's favour— a J$12,000 panel that catches pre-diabetes early is worth far more than the cost of managing full Type 2 diabetes over 10 years.
The Lancet · 2021
AI-enhanced diagnostic interpretationimproves detection rates by 37%.
Nature Medicine's 2023 study found that AI-enhanced lab diagnostics improved disease detection rates significantly over standard lab reporting alone. The reason: pattern recognition across multiple biomarkers that a standard reference-range report misses.This is the evidence base behind Clariti— not just interpretation convenience, but clinical accuracy.
Nature Medicine · 2023
The conditions most relevantto the Jamaican population.
Our panels are not generic. They're structured around the specific disease burden Jamaica faces and the biomarkers with the strongest evidence base for early detection in this population.
Diabetes &blood sugar.
HbA1c and fasting glucose tests can predict Type 2 diabetesup to 10 years before onset.At the pre-diabetes stage, the condition is reversible with dietary and lifestyle intervention — no medication required. Once full Type 2 diabetes develops, the management window narrows significantly.
Addressed by
Essentials · Cardiovascular Health
Heart disease &hypertension.
High-sensitivity CRP and Lipoprotein(a) are critical indicators of hidden cardiovascular risk that standard cholesterol checks miss.Caribbean populations carry specific cardiovascular risk patternsthat differ from Western populations — the panels we use reflect this.
Addressed by
Cardiovascular Health · Essentials
Thyroid &hormonal balance.
Thyroid dysfunction affects an estimated 1 in 10 adults — the majority undiagnosed.Fatigue, weight changes, brain fog, and mood disruptionare among the most common symptoms, and among the most commonly attributed to other causes. A simple TSH test is one of the highest-yield screenings available.
Addressed by
PCOS & Hormonal Balance · Essentials
Deficiencies thatdrive symptoms.
Vitamin D deficiency affects a substantial proportion of Jamaican adults despite high sun exposure — because sun exposure alone does not guarantee adequate Vitamin D synthesis.Deficiencies in Vitamin D, B12, iron, and folatedrive symptoms that are frequently mistaken for lifestyle issues rather than treatable nutritional gaps.
Addressed by
Nutritional Health · Essentials
Silent organstress.
Kidney and liver dysfunction are among the most asymptomatic conditions in early development. By the time pain, swelling, or colour changes are noticeable,significant damage has already occurred.Creatinine, eGFR, ALT, and AST provide early warning years before clinical presentation.
Addressed by
Essentials · Immunity & Inflammation
Chronic inflammationas an underlying driver.
Emerging research consistently identifies chronic low-grade inflammation as a shared pathway across cardiovascular disease, metabolic syndrome, cognitive decline, and certain cancers.hs-CRP and IL-6 markerscan detect this inflammatory state years before it manifests as a named condition.
Addressed by
Immunity & Inflammation · Cardiovascular Health
A result you can't understandis not a result.
The research on patient health literacy is consistent: when people receive lab results they cannot interpret, they do one of two things. They ignore them. Or they Google them and arrive at the most alarming possible conclusion.
Neither outcome serves the purpose of screening. The value of proactive testing is not in generating a PDF — it's in the action that PDF enables.Clariti exists to close that gap.
The evidence base for AI-assisted interpretation is no longer theoretical. Multiple peer-reviewed studies have demonstrated that AI-enhanced diagnostics improve detection rates, reduce patient confusion, and lead to faster, more appropriate clinical decisions. The studies below are the ones we reference when we explain why interpretation is not a nice-to-have.
Clariti is not a diagnosis. It is interpretation — the same thing a good doctor does when they sit down and explain what your results mean. We've made that explanation available to everyone, not just to those who can afford a lengthy GP consultation after every blood draw.
AI-enhanced lab diagnostics improved disease detection rates by37% over standard lab reporting alone— driven by pattern recognition across multiple biomarkers that reference-range reports miss.
Nature Medicine · 2023
AI-powered health reports have been shown to reduce patient confusion by50%, improving health literacy and engagement with recommended next steps.
Harvard Medical School review · 2022
A Harvard Medical School review concluded thatAI-driven clinical insights help doctors make faster, more accurate decisions— reducing the time between detection and intervention.
Harvard Medical School · 2022
Preventive screenings with clear, actionable follow-up recommendations reduce long-term healthcare costs by40%through reduced emergency care and hospitalisations.
The Lancet · 2021
The research cited on this page comes from published, peer-reviewed sources. LifeVitals has not conducted independent clinical studies. The statistics cited in the Jamaica and Caribbean context are drawn from PAHO, WHO, and Jamaica Ministry of Health data.LifeVitals panels are designed for proactive screening, not diagnosis.If you have a current health concern or medical emergency, consult a qualified medical professional. The evidence on this page supports the case for proactive screening — it does not replace clinical judgment.
— The evidence is there —
The question isn't whetherto check. It's when.
Free · 60 seconds · No referral required